During Thursday’s current trade, Advaxis, Inc. (NASDAQ:ADXS)’s shares decline -4.26% to $21.55.
Advaxis, Inc. (ADXS) stated financial results for fiscal second quarter ended April 30, 2015.
No revenue recorded for the three months ended April 30, 2015, as contrast to $1 million in revenue for fiscal second quarter of 2014 from the upfront payment by Aratana for licensing certain Advaxis proprietary technology that enables Aratana to develop and commercialize animal health products that will be targeted for treatment of osteosarcoma and other cancer indications in animals.
R&D expense was $6.1 million for the three months ended April 30, 2015, contrast with $1.5 million for the three months ended April 30, 2014. The enhance of $4.6 million was primarily a result of higher third-party costs, specifically related to ADXS-HPV support in manufacturing and clinical trial expenses, for the Anal, Head & Neck, High Dose, and Cervical Cancer programs, in addition to ADXS-PSA Phase I/II trial start-up support. In addition, greater stock based compensation costs and an raised headcount contributed to the enhance.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, accomplished its Phase II study.
Plug Power Inc (NASDAQ:PLUG)‘s shares gain 0.39% to $2.60, during the current trading session Thursday’s, hitting its highest level.
Plug Power Inc. (PLUG) in the fuel systems and storage business. It hit the mainstream news rounds when the stock rose literally from pennies to about $12 in stock price. Since then, the stock has fallen back down over 80%. The run up was a bit of bad money chasing overblown momentum, but the fundamentals surrounding the firm did drastically change for the better. That’s simply a fact. All of a sudden the company is signing multi-million dollar contracts and to date, those contracts have (for the most part) come in.
On the other hand, the company has never turned a profit or positive free cash flow and it is sustaining operations with a rather sizeable stock selling program. But, love it or hate it, PLUG has seen revenue (TTM) rise over both one- and two-years by 164.55% and 174.46%, respectively. Revenue in the most recent trailing-twelve-months is $68 million. Last year PLUG stated $26 million and two-years ago annual revenue was $25.
The average estimate for next quarter’s revenue of $19.7 million is well above last quarter’s $9.4 million. In English, revenue is busting at the seams. It’s everything else that’s the problem.
Plug Power Inc., an alternative energy technology provider, engages in the design, development, manufacture, and commercialization of fuel cell systems for the industrial off-road markets worldwide. It focuses on proton exchange membrane (PEM) fuel cell and fuel processing technologies, and fuel cell/battery hybrid technologies.
In a mid-morning trade, Intrexon Corp (NYSE:XON)‘s shares surge 1.73% to $49.40.
Intrexon Corporation (XON) declared that it has reached a partnership with an investment fund sponsored by Harvest Capital Strategies, LLC. The fund is believed to be the world’s first that is dedicated to the inventions and discoveries of a single company.
Intrexon has agreed to provide the fund a noteworthy number of investment proposals from across five sectors – Health, Energy, Food, Environment and Consumer – that are suitable for pursuit by a startup, counting several in 2015. With respect to such proposals, Intrexon will provide the fund with exclusive rights of first-look and first negotiation. Intrexon presently sees the potential to form up to ten new companies per year, each of which will have access to Intrexon’s proprietary technology platform through an Exclusive Channel Collaboration. Although the partnership with the fund will be complimentary to programs already underway at Intrexon, nothing in the arrangement will limit the Company’s ability to execute other collaborations and joint ventures.
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components. Its technologies comprise UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has partnership agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC; and planned partnershipand licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Corelogic Inc (NYSE:CLGX), during its Thursday’s current trading session 0.43% gain and closed at $37.70.
CoreLogic® (CLGX), a leading global property information, analytics and data-enabled services provider, released new analysis showing 254,000 properties regained equity in the first quarter of 2015, bringing the total number of mortgaged residential properties with equity at the end of Q1 2015 to approximately 44.9 million, or 90 percent of all mortgaged properties. Nationwide, borrower equity increased year over year by $694 billion in Q1 2015. The total number of mortgaged residential properties with negative equity is now at 5.1 million, or 10.2 percent of all mortgaged properties. This compares to 5.4 million homes, or 10.8 percent, that had negative equity in Q4 2014*, a quarter-over-quarter decrease of 4.7 percent. Compared with 6.3 million homes, or 12.9 percent, reported for Q1 2014, the number of underwater homes has decreased year over year by 1.2 million, or 19.4 percent.
Negative equity, often referred to as “underwater” or “upside down,” refers to borrowers who owe more on their mortgages than their homes are worth. Negative equity can occur because of a decline in value, an enhance in mortgage debt or a combination of both.
For the homes in negative equity status, the national aggregate value of negative equity was $337.4 billion at the end of Q1 2015, falling about $11.7 billion from $349.1 billion in Q4 2014. On a year-over-year basis, the value of negative equity declined overall from $388 billion in Q1 2014, representing a decrease of 13 percent in 12 months.
CoreLogic, Inc. provides property information, analytics, and data-enabled services in North America, Western Europe, and the Asia Pacific. The company operates through two segments, Technology and Processing Solutions and Data & Analytics (D&A). The Technology and Processing Solutions segment offers property tax monitoring, flood zone certification and monitoring, credit services, mortgage loan administration and production services, lending solutions, mortgage-related business process outsourcing, technology solutions and compliance-related services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
